P21
Status unknownP21 is classified under other / experimental.
What the research says
Aggregated from the cited literature below. We summarize sources — we don't author claims.
The provided sources do not specifically define a peptide named “P21.” However, multiple studies discuss peptides involving oncogenic KRAS neoantigens and related “p21” terminology in other contexts. For example, KRAS mutant neoantigen peptides are used to engineer immune therapies targeting KRAS-mutant tumors, including CAR-T approaches and defined TCR-recognized peptides.
Mechanism (as reported)
null
Key findings (each cites a source)
- A study reported developing CAR-T cells that target tumors using binders against oncogenic KRAS G12V peptide-MHC complexes, incorporating neoantigen binders into CAR-T cells, and demonstrating efficacy in xenograft models (metastatic lung, pancreatic, and renal cell cancer). [PMID 40480232]
- The same study reported enhancing in vivo efficacy and safety of the KRAS-targeted CAR-T approach via inducible IL-12 secretion and T cell receptor deletion. [PMID 40480232]
- Research integrating proteogenomics and other datasets reported prioritizing mutant KRAS peptides as promising public neoantigens by combining proteomic data with MHC binding prediction. [PMID 38917788]
- A study reported identifying two TCRs specific for a 9-mer KRAS-G12V mutant neoantigen presented by HLA-A*11:01 and observing cytokine secretion and cytotoxicity when TCR-T cells were co-cultured with tumor cells expressing the KRAS-G12V mutation. [PMID 37828002]
- That TCR study reported that specific recognition of the KRAS-G12V mutant depends on distinct peptide conformation relative to wildtype and the direct interaction with TCR residues. [PMID 37828002]
- A study reported that a covalent K-Ras(G12C)-mutant inhibitor can induce MHC class I presentation of haptenated peptide neoepitopes in KRAS G12C mutant cells and that haptenated MHC-I complexes can serve as tumor-specific neoantigens. [PMID 36099883]
- The same covalent-inhibitor study reported that an ARS1620-specific antibody-based bispecific T cell engager elicited cytotoxic T cell responses against KRAS G12C cells, including those resistant to direct KRAS G12C inhibition. [PMID 36099883]
- A study reported that Klotho-derived peptide 1 (KP1) inhibited cellular senescence and restored Klotho expression at the posttranscriptional level, with effects including reduced senescence markers p21, p16, and γ-H2AX in diseased kidneys. [PMID 38164143]
- A separate study reported that a recombinant walnut-derived peptide (rWDP) was associated with decreased p21 expression in the hippocampus and cortex in d-galactose-induced aging mice. [PMID 40864666]
Independent test grades
No independent third-party test data is available for P21 yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.
Research literature (8)
Consolidated from PubMed — each links to the original record.
- Recombinant Walnut-Derived Peptide Ameliorates d-Galactose-Induced Cognitive Deficits.
Li C, Zheng D, Zhang T, Qian S, Liu X, Yang Z · Journal of agricultural and food chemistry · 2025 · PMID 40864666
- Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.
Benton A, Liu J, Poussin MA, Lang Goldgewicht A, Udawela M, Bear AS · Cancer cell · 2025 · PMID 40480232
- Pan-cancer proteogenomics expands the landscape of therapeutic targets.
Savage SR, Yi X, Lei JT, Wen B, Zhao H, Liao Y · Cell · 2024 · PMID 38917788
- Klotho-derived peptide 1 inhibits cellular senescence in the fibrotic kidney by restoring Klotho expression via posttranscriptional regulation.
Zhang X, Li L, Tan H, Hong X, Yuan Q, Hou FF · Theranostics · 2024 · PMID 38164143
- Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor.
Tanada M, Tamiya M, Matsuo A, Chiyoda A, Takano K, Ito T · Journal of the American Chemical Society · 2023 · PMID 37463267
- KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors.
Lu D, Chen Y, Jiang M, Wang J, Li Y, Ma K · Nature communications · 2023 · PMID 37828002
- A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy.
Zhang Z, Rohweder PJ, Ongpipattanakul C, Basu K, Bohn MF, Dugan EJ · Cancer cell · 2022 · PMID 36099883
- Plasmid expression of a peptide that selectively blocks oncogenic ras-p21-induced oocyte maturation.
Kovac C, Clie L, Morin J, Friedman FK, Robinson R, Chung DL · Cancer chemotherapy and pharmacology · 2001 · PMID 11488531
FAQ
- What is P21?
- P21 is classified under other / experimental. Research goals associated with it include cognitive & mood.
- Is P21 FDA-approved?
- The regulatory status of P21 is not established in our sources.
- What does the research on P21 say?
- peptideone aggregates 8 references from PubMed for P21. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.